Niagen Bioscience Posts 30% Revenue Growth to $129.4M, Eyes 15% 2026 Outlook
Niagen Bioscience reported 2025 net sales rose 30% year-over-year to $129.4 million with net income doubling to $17.7 million, beating its forecast. The company ended the year with $64.8 million cash, zero debt, and projected 2026 revenue of $145 million (15% growth) while exploring potential acquisitions.
1. Strong 2025 Financial Results
Niagen Bioscience’s full-year 2025 net sales increased 30% to $129.4 million and net income rose to $17.7 million, roughly double the prior year, marking its strongest annual performance to date.
2. Robust Balance Sheet
The company closed 2025 with $64.8 million in cash and zero debt, providing significant financial flexibility for strategic initiatives.
3. 2026 Guidance and Strategic Plans
Management projects $145 million in 2026 revenue, representing approximately 15% growth, and CEO Rob Fried is actively evaluating acquisition targets and exploring market expansions into at-home injection kits and cosmetics partnerships.
4. Stock Performance and Valuation Metrics
Shares jumped 18.41% in after-hours trading to $5.85 following the earnings release; the stock trades near its 52-week low of $4.73, carries a market capitalization of $394 million, and holds an RSI of 36.98.